I was wondering when you were going to post that one. :)

Actually, in reference to my original reply to you, I have no idea what I'm talking about. I wish I could just delete my post and just say thank you for posting. I have no idea what they're going to do in the study and it would be awesome if they are able to come up with different formulations of there lipid-based dronabinol that are contoured to better meet the needs of different subsets of patients suffering from OSA to give patients a better chance for success.

RSPI amended their agreement with UIC a little over a year ago so I have a good feeling that whatever the objective of this study is, RSPI will be part of the equation and benefit from the information obtained in the study.

I should have said "...which you had viewed?".

That's great DD...thank you very much!

Is this the URL which you had viewing? https://clinicaltrials.gov/study/NCT06477952?id=NCT06477952&rank=1&tab=history&a=2#version-content-panel

The language from that link that I see here looks as though they are trying to identify the right kind of candidate for enrollment in a clinical trial in an effort maximize the likelihood of clinical success:

This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.

If you go to the webpage https://ipsearch.ipaustralia.gov.au/patents/2023238872 it only shows the application status as Filed, not Granted.

Does anyone know the bid/ask?

Is that information about RSPI recently applying for a patent behind a paywall?

I'm sorry LTL but I don't know much about the topic of patents and so I am unable to properly answer any of your questions.

"National Phase: after the end of the PCT procedure, usually at 30 months from the earliest filing date of your initial application, from which you claim priority, you start to pursue the grant of your patents directly before the national (or regional) patent Offices of the countries in which you want to obtain them."

https://www.wipo.int/pct/en/faqs/faqs.html

---------------------------------------------------------

You can go to https://ipsearch.ipaustralia.gov.au/patents/2023238872 and see the details on the application. They only recently entered National Stage Entry, which means now their patent application can be examined by a PCT country, in this case Australia.

Thank you!

If this is a serious post then I would suggest you call the transfer agent.

From https://www.otcmarkets.com/stock/RSPI/security:

Outstanding Shares
949,463,730
11/01/2024

It's been the wrong share count on iHub for a while now.

Does anyone know the bid/ask? TIA

Thank you brother. 👍

English.

Would anyone mind sharing with me the bid/ask? TIA.

I read in an old Cortex Pharmaceuticals SEC filing that the patent for CX929 was set to expire in Nov. 2022. You know more about all this stuff than me, but I was just wondering, if there is no longer any patent protection for RespireRx on the molecule? And if that was the case, how could RespireRx expect to benefit from positive developments on the research front related to that molecule?

Test.

I think it's worth mentioning that Dr. Lippa presented at the 5th annual installment of the same conference a couple years back, and that RespireRx representatives presented at the inaugural conference and the year two conference as well. So while exposure is a good thing it's probably not worth reading too much into their upcoming presentations in terms of gauging how far along their cannabinoid program is.

https://www.biospace.com/respirerx-pharmaceuticals-inc-announces-that-dr-arnold-lippa-is-an-invited-speaker-at-the-5th-international-cannabinoid-derived-pharmaceuticals-summit

https://markets.businessinsider.com/news/stocks/respirerx-pharmaceuticals-inc-executives-participating-in-the-2nd-annual-international-cannabinoid-derived-pharmaceuticals-summit-1028510435

https://www.marketscreener.com/quote/stock/RESPIRERX-PHARMACEUTICALS-5787161/news/RespireRx-Pharmaceuticals-Inc-Executives-Presenting-at-the-International-Cannabinoid-Derived-Pharma-27731174/

Good find! After checking out the website you had posted I also Dr. Lippa is scheduled to present as well.

Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers

Daniel P. Radin, Rok Cerne, Jeffrey M. Witkin, Arnold Lippa

First published: 20 September 2024
https://doi.org/10.1002/cpdd.1475

Abstract
AMPA-type glutamate receptors (AMPARs) mediate the majority of fast excitatory synaptic transmission in the mammalian brain. Ampakines, positive allosteric modulators of AMPAR, hold significant potential for the treatment of a wide range of neurological/neuropsychiatric disorders in which excitatory synaptic transmission is compromised. Low-impact ampakines are a distinct subset of ampakines that accelerate channel opening yet minimally affect receptor desensitization, which may explain their lack of seizurogenic effects at therapeutic doses in preclinical models. CX1739 is a low-impact ampakine that has shown efficacy in preclinical studies. The current clinical study examined the tolerability and pharmacokinetics of CX1739 in healthy male volunteers in a 2-part study. Part A was a single dose escalation study (100-1200 mg, 48 patients) and Part B was a multiple dose ascending study (300-600 mg BID for 7-10 days, 32 patients). CX1739 was well tolerated up to 900 mg once daily (QD) and 450 mg twice a day, with the prominent side effects being headache and nausea. Importantly, the half-life of CX1739 was 6-9 hours, and Tmax was 1-5 hours. CX1739 Cmax and AUC were dose-proportional. These findings thus set the stage for further explorations of this drug candidate in phase 2 clinical studies.

Conflicts of Interest
RespireRx Pharmaceuticals is developing CX1739 for the treatment of opiate-induced respiratory depression, ADHD, and spinal cord injury. Daniel Radin, Rok Cerne, Jeffrey Witkin, and Arnold Lippa are associated with RespireRx, where Arnold Lippa is acting CEO, and Daniel P. Radin, Rok Cerne, and Jeffrey M. Witkin are non-paid researchers who occasionally conduct studies on these compounds.

Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763

Daniel P Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jeffrey M Witkin & Arnold Lippa

Received 28 May 2024, Accepted 02 Sep 2024, Published online: 20 Sep 2024

Cite this article
https://doi.org/10.1080/17568919.2024.2401312

Abstract
Aim: AMPA-glutamate receptor (AMPAR) dysfunction mediates multiple neurological/neuropsychiatric disorders. Ampakines bind AMPARs and allosterically enhance glutamate-elicited currents. This report describes the activity of the water-soluble ampakine CX1942 prodrug and the active moiety CX1763.

Results: CX1763 and CX1942 enhance synaptic transmission in hippocampi of rats. CX1763 increases attention in the 5CSRTT in rats and reduces amphetamine-induced hyperactivity in mice. CX1942 potently reverses opioid-induced respiratory depression in rats. CX1942/CX1763 was effective at 2.5–10 mg/kg. CX1763 lacked epileptogenicity up to 1500 mg/kg in rats.

Conclusion: These data document that CX1942 and CX1763 are active and without prominent side effects in multiple pre-clinical assays. CX1942 could serve as a prodrug for CX1763 with the advantage of high water solubility as in an intravenous formulation.

Article highlights
The water-soluble glycine ester pro-drug of CX1763, CX1942 is potent and active against alfentanil-induced respiratory depression in vivo

CX1942 and CX1763 produce a durable increase in hippocampal EPSP in vivo

CX1763 increases metrics of attention in rodents while reducing hyperactivity associated with amphetamine, indicating multiple potential benefits for ADHD treatment

CX1763/CX1942 is therapeutically active at doses of 2.5–10 mg/kg and CX1763 lacks epileptic and fatal toxicities up to 1500 mg/kg, demonstrating a notable safety margin, justifying further preclinical and clinical explorations

I bought 250,000 and 190,600 on Thursday at 3:46 PM. If there were other 0.0013 prints that day they weren't mine.

Yessir. EOM

I was doing pretty much all of the buying and I believe me when I say I don't know anything. I just think that the shares are cheap down here and I wanted fills and I was willing to overpay a little if necessary to get them.

This post doesn't really jive with your previous post, IMO.

Thanks!

Hey man, what is the bid/ask now?

https://www.td.com/ca/en/investing/direct-investing/trading/webbroker

In Canada there is still a TD.

Just wondering what is the bid/ask now? Thanks very much!!

Thank you!

Her man, I was wondering what is the current bid/ask?

That 11 am trade that you mentioned took place on Friday. On the Quotemedia time and sales page for an RSPI quote they have the timestamp as well as the date.

https://quotemedia.com/portal/time_sales?qm_symbol=Rspi

Thanks very much for posting all of these, meixatech.

RespireRx owed their auditor money which was their excuse for not getting any audit done on their then and still delinquent annual filing. As a result of not being current with their filings they have been punted to the Expert Market. I'm not really sure what they plan on doing from this point. Also, I'm not sure about the ease at which a delinquent turned current company would enjoy in terms of getting off the Expert Market, just in case you were wondering about their being stuck here thing even if they wanted to get current and have the stock properly quoted again. Others may know more about both those topics, however.

If I were to hazard a guess, I believe the move to Expert Market was to allow the IP to be developed without the company's PPS being massively undervalued *and* trading on a liquid market, for fear of a hostile takeover.

If RespireRx is able to effectively advance their IP on the Expert Market it would mean that they could reemerge to active trading with a story in place to drive valuations to a place much, much higher than where we currently are.

His LinkedIn says he left his position of Principal Research Scientist at Eli Lilly in Mar. 2018.

TYVM.

The last 10-K ERHE filed was in 2017 but it's still on the Expert Market. The SEC sought revocation in 2019 and it was denied by the courts in 2020.

Personally I'm disgusted by the fact this stock is going to the Expert Market but I don't think it's certain death as you keep ascribing.

It's possibly different in Canada. But in Canada you'll need a Canadian address to open an account. JMHO